Why the study?
Current antihypertensive therapies inhibit both the N-domain and C-domain of ACE, often causing undesirable side effects, whereas simultaneous cACE-selective and neprilysin inhibition has shown improved pharmacological efficacy in hypertensive mice.
Comparison
Dual cACE/NEP inhibitors AD017, AD018, and AD019
Design
Enzyme kinetic analyses and X-ray crystallography
Answers are grounded in this paper and cite their sources.
Identifies dual cACE and neprilysin inhibitors with ten-fold domain selectivity, indicating structural pathways for targeted antihypertensive drug design.
Cardiovascular diseases, driven primarily by hypertension, depend on blood pressure regulation through the renin-angiotensin-aldosterone system (RAAS), endothelin system (ES), and natriuretic peptide and kinin system (NPKS). These pathways require balanced peptide processing by enzymes such as angiotensin-converting enzyme (ACE) and neprilysin (NEP). Current antihypertensive therapies inhibit both the N-domain (nACE) and C-domain (cACE) of ACE, often causing undesirable side effects. To address this, cACE-selective inhibitors have been developed, while simultaneous inhibition of cACE and NEP has demonstrated improved pharmacological efficacy in hypertensive mice. Enzyme kinetic analyses and X-ray crystallography identified three dual cACE/NEP inhibitors (AD017, AD018, and AD019), each exhibiting approximately 10-fold selectivity for cACE over nACE. Notably, AD019 combined this cACE selectivity with low-nanomolar NEP inhibition, making it the most promising lead. These findings demonstrate that hydrophobic P1/P1′ residues and a bulky aromatic P2′ group optimally exploit the hydrophobic subsites of cACE and NEP for drug design.
No takes yet. Share an insight, caveat, or question.
Żukowska et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: